source
- Vera Therapeutics' Trutakna shows kidney function stabilization and lower death risk in Phase 3 IgAN trialVera Therapeutics reported that its drug Trutakna met its primary goals in a two‑year Phase 3 study of patients with IgA nephropathy. The therapy stabilized kidney function and lowered the risk of…
- New documents expose flaws in Medicare’s rushed AI prior-authorization pilotNew internal documents have highlighted serious shortcomings in Medicare’s recently launched AI-driven prior‑authorization pilot, which was rolled out faster than anticipated. The pilot, designed…